Investigate the safety and tolerability of olaparib tablet in Japanese patients with advanced solid malignancies

Study identifier:D081BC00001

ClinicalTrials.gov identifier:NCT01813474

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase I, open-label study to assess the safety and tolerability of doses of olaparib tablet in Japanese patients with advanced solid malignancies

Medical condition

cancer

Phase

Phase 1

Healthy volunteers

No

Study drug

olaparib

Sex

All

Actual Enrollment

23

Study type

Interventional

Age

20 Years - 130 Years

Date

Study Start Date: 25 Mar 2013
Primary Completion Date: 31 Aug 2016
Study Completion Date: 31 Aug 2016

Study design

Allocation: N/A
Endpoint Classification: Safety
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Dec 2017 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria